Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today
29 sept. 2020 12h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that the Company will host...
Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol in NASH Cirrhosis
30 avr. 2020 09h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 30, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has...
Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis
11 nov. 2019 09h47 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Today, Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced a collaboration...
Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapy
17 sept. 2019 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute...
Galectin Therapeutics Reports Q2 2019 Financial Results and Provides Business Update
09 août 2019 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...
Galectin Therapeutics Submits Phase 3 NASH-RX Protocol in Nash Cirrhosis to FDA
05 août 2019 08h05 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced it has submitted for...
Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million from Warrant Exercise
28 mai 2019 09h05 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., May 28, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced its Rights Offering...
Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders Dated May 10, 2019
10 mai 2019 08h05 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., May 10, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today released this open letter to...
Galectin Therapeutics Reports Q1 2019 Financial Results and Provides Business Update
10 mai 2019 08h00 HE
|
Galectin Therapeutics Inc.
Subscription rights to purchase Galectin Therapeutics, Inc. common shares, with accompanying warrants, mailed to Holders of Record as of April 29. Rights expire at 5:00 PM Eastern on May 23, 2019 ...
Galectin Therapeutics Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of its Registration Statement
15 avr. 2019 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 15, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has set key...